F2G

F2G is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat life-threatening invasive fungal infections. The company has discovered and developed a completely new class of antifungal agents called the orotomides, which have a distinct mechanism of action, selectively targeting fungal dihydroorotate dehydrogenase (DHODH), a key enzyme in the de novo pyrimidine biosynthesis pathway. This differentiation from currently marketed antifungal agents positions F2G as an innovative player in the industry. Olorofim (formerly F901318) is the leading candidate from this class and has fungicidal activity against a broad range of mold infections including rare and resistant molds, addressing infections for which current therapies have limitations or are ineffective. It is currently in a Phase 2b open-label study focusing on rare and resistant invasive fungal infections including invasive aspergillosis (including azole-resistant strains), coccidioidomycosis, and scedosporiosis (including lomentosporiosis). Notably, Olorofim has received orphan drug status from the European Medicines Agency as well as orphan drug status, Qualified Infectious Disease Product (QIDP) designation, and Breakthrough Therapy designation from the FDA. Founded in 1998 and headquartered in the United Kingdom with subsidiaries in the US and Austria, F2G recently secured a $70.00M Private Equity Round investment on 04 August 2022 led by Sofinnova Partners and Forbion. This strategic investment further reinforces the company's position in the biotechnology, healthcare, and pharmaceutical industries, signifying its potential for growth and development in the market.